Prognostic Role of High-Sensitivity C-Reactive Protein/Albumin Ratio in Heart Failure Patients

Area of Science:

• Cardiology
• Biomarkers
• Clinical Risk Stratification

Background:

• Chronic heart failure (CHF) poses a significant cardiovascular risk.
• Identifying reliable biomarkers for risk stratification in CHF is crucial.
• The hs-CRP/SA ratio is an emerging biomarker for cardiovascular risk.

Purpose of the Study:

• To evaluate the long-term prognostic value of the hs-CRP/SA ratio.
• To assess the risk of major adverse cardiovascular events (MACEs) in outpatients with CHF.
• To determine if the hs-CRP/SA ratio can stratify cardiovascular risk in CHF patients.

Main Methods:

• Retrospective observational study of 500 outpatients with CHF.
• Stratification into two groups based on the median hs-CRP/SA ratio (<1.19 and ≥1.19).
• Median follow-up of 5.2 years to track MACE incidence.

Main Results:

• Patients with hs-CRP/SA ≥ 1.19 experienced a MACE incidence of 5.9 events/100 patient-years versus 1.2 events/100 patient-years for hs-CRP/SA < 1.19 (p < 0.001).
• Multivariate analysis revealed hs-CRP/SA ≥ 1.19 was associated with a 6.5-fold increased risk of MACEs (HR 6.513, p < 0.001).
• The hs-CRP/SA ratio demonstrated significant predictive power for MACEs.

Conclusions:

• The hs-CRP/SA ratio is a potent prognostic marker in CHF.
• Elevated hs-CRP/SA ratios are significantly associated with increased MACE risk.
• This ratio aids in stratifying cardiovascular risk in CHF outpatients.